|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TOPICAL REVIEW |
The John Hopkins University School of Medicine, Department of Medicine, Cardiology Division, Johns Hopkins Hospital, Baltimore, MD, USA
There is substantial evidence that oxidative stress participates in the pathophysiology of cardiovascular disease. Biochemical, molecular and pharmacological studies further implicate xanthine oxidoreductase (XOR) as a source of reactive oxygen species in the cardiovascular system. XOR is a member of the molybdoenzyme family and is best known for its catalytic role in purine degradation, metabolizing hypoxanthine and xanthine to uric acid with concomitant generation of superoxide. Gene expression of XOR is regulated by oxygen tension, cytokines and glucocorticoids. XOR requires molybdopterin, ironsulphur centres, and FAD as cofactors and has two interconvertible forms, xanthine oxidase and xanthine dehydrogenase, which transfer electrons from xanthine to oxygen and NAD+, respectively, yielding superoxide, hydrogen peroxide and NADH. Additionally, XOR can generate superoxide via NADH oxidase activity and can produce nitric oxide via nitrate and nitrite reductase activities. While a role for XOR beyond purine metabolism was first suggested in ischaemiareperfusion injury, there is growing awareness that it also participates in endothelial dysfunction, hypertension and heart failure. Importantly, the XOR inhibitors allopurinol and oxypurinol attenuate dysfunction caused by XOR in these disease states. Attention to the broader range of XOR bioactivity in the cardiovascular system has prompted initiation of several randomised clinical outcome trials, particularly for congestive heart failure. Here we review XOR gene structure and regulation, protein structure, enzymology, tissue distribution and pathophysiological role in cardiovascular disease with an emphasis on heart failure.
(Received 26 September 2003;
accepted after revision 16 December 2003;
first published online 23 December 2003)
Corresponding author J. M. Hare: The Johns Hopkins Hospital School of Medicine, Cardiology Division, 600 N Wolfe Street, Carnegie 568, Baltimore, MD 21287, USA. Email: jhare{at}mail.jhmi.edu
This article has been cited by other articles:
![]() |
E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF] |
||||
![]() |
A. Boueiz, M. Damarla, and P. M. Hassoun Xanthine oxidoreductase in respiratory and cardiovascular disorders Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L830 - L840. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Schwarzschild, S. R. Schwid, K. Marek, A. Watts, A. E. Lang, D. Oakes, I. Shoulson, A. Ascherio, and and the Parkinson Study Group PRECEPT Investigator Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease Arch Neurol, April 14, 2008; (2008) 2008.65.6.nct70003. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Sanchez-Lozada, E. Tapia, P. Bautista-Garcia, V. Soto, C. Avila-Casado, I. P. Vega-Campos, T. Nakagawa, L. Zhao, M. Franco, and R. J. Johnson Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome Am J Physiol Renal Physiol, April 1, 2008; 294(4): F710 - F718. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Pauff, J. Zhang, C. E. Bell, and R. Hille Substrate Orientation in Xanthine Oxidase: CRYSTAL STRUCTURE OF ENZYME IN REACTION WITH 2-HYDROXY-6-METHYLPURINE J. Biol. Chem., February 22, 2008; 283(8): 4818 - 4824. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lim, L. Venetucci, D. A. Eisner, and B. Casadei Does nitric oxide modulate cardiac ryanodine receptor function? Implications for excitation-contraction coupling Cardiovasc Res, January 15, 2008; 77(2): 256 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Lu, X. Xu, X. Hu, G. Zhu, P. Zhang, E. D. van Deel, J. P. French, J. T. Fassett, T. D. Oury, R. J. Bache, et al. Extracellular Superoxide Dismutase Deficiency Exacerbates Pressure Overload Induced Left Ventricular Hypertrophy and Dysfunction Hypertension, January 1, 2008; 51(1): 19 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. J. Bone and J. R. Hammond Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: characterization of a novel nucleobase transporter Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3325 - H3332. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Seddon, Y. H Looi, and A. M Shah Oxidative stress and redox signalling in cardiac hypertrophy and heart failure Heart, August 1, 2007; 93(8): 903 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Funakoshi, L. C. Zacharia, Z. Tang, J. Zhang, L. L. Lee, J. C. Good, D. E. Herrmann, Y. Higuchi, W. J. Koch, E. K. Jackson, et al. A1 Adenosine Receptor Upregulation Accompanies Decreasing Myocardial Adenosine Levels in Mice With Left Ventricular Dysfunction Circulation, May 1, 2007; 115(17): 2307 - 2315. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zhang, X. Xu, X. Hu, E. D. van Deel, G. Zhu, and Y. Chen Inducible Nitric Oxide Synthase Deficiency Protects the Heart From Systolic Overload-Induced Ventricular Hypertrophy and Congestive Heart Failure Circ. Res., April 13, 2007; 100(7): 1089 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Landmesser, S. Spiekermann, C. Preuss, S. Sorrentino, D. Fischer, C. Manes, M. Mueller, and H. Drexler Angiotensin II Induces Endothelial Xanthine Oxidase Activation: Role for Endothelial Dysfunction in Patients With Coronary Disease Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 943 - 948. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Asai, T. Nishino, T. Matsumura, K. Okamoto, K. Igarashi, E. F. Pai, and T. Nishino Two Mutations Convert Mammalian Xanthine Oxidoreductase to Highly Superoxide-productive Xanthine Oxidase J. Biochem., April 1, 2007; 141(4): 525 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Saliaris, L. C. Amado, K. M. Minhas, K. H. Schuleri, S. Lehrke, M. St. John, T. Fitton, C. Barreiro, C. Berry, M. Zheng, et al. Chronic allopurinol administration ameliorates maladaptive alterations in Ca2+ cycling proteins and beta-adrenergic hyporesponsiveness in heart failure Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1328 - H1335. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Silver, S. D. Beske, D. D. Christou, A. J. Donato, K. L. Moreau, I. Eskurza, P. E. Gates, and D. R. Seals Overweight and Obese Humans Demonstrate Increased Vascular Endothelial NAD(P)H Oxidase-p47phox Expression and Evidence of Endothelial Oxidative Stress Circulation, February 6, 2007; 115(5): 627 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Erdei, A. Toth, E. T. Pasztor, Z. Papp, I. Edes, A. Koller, and Z. Bagi High-fat diet-induced reduction in nitric oxide-dependent arteriolar dilation in rats: role of xanthine oxidase-derived superoxide anion Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2107 - H2115. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Zimmet and J. M. Hare Nitroso-Redox Interactions in the Cardiovascular System Circulation, October 3, 2006; 114(14): 1531 - 1544. [Full Text] [PDF] |
||||
![]() |
C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure Cardiovasc Res, July 15, 2006; 71(2): 208 - 215. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Gao, K. Takemori, L.-Y. Su, W.-S. An, C. Lu, A. M. Sharma, and R. M.K.W. Lee Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion Cardiovasc Res, July 15, 2006; 71(2): 363 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Davidson and M. R. Duchen Effects of NO on mitochondrial function in cardiomyocytes: Pathophysiological relevance Cardiovasc Res, July 1, 2006; 71(1): 10 - 21. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Rubio-Gayosso, S. H. Platts, and B. R. Duling Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2247 - H2256. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Zweier and M.A. H. Talukder The role of oxidants and free radicals in reperfusion injury Cardiovasc Res, May 1, 2006; 70(2): 181 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ardanaz and P. J. Pagano Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Experimental Biology and Medicine, March 1, 2006; 231(3): 237 - 251. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pacher, A. Nivorozhkin, and C. Szabo Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev., March 1, 2006; 58(1): 87 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Daghini, A. R. Chade, J. D. Krier, D. Versari, A. Lerman, and L. O. Lerman Acute inhibition of the endogenous xanthine oxidase improves renal hemodynamics in hypercholesterolemic pigs Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R609 - R615. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Hajjar and J. A. Leopold Xanthine Oxidase Inhibition and Heart Failure: Novel Therapeutic Strategy for Ventricular Dysfunction? Circ. Res., February 3, 2006; 98(2): 169 - 171. [Full Text] [PDF] |
||||
![]() |
S. Al-Benna, C. A. Hamilton, J. D. McClure, P. N. Rogers, G. A. Berg, I. Ford, C. Delles, and A. F. Dominiczak Low-Density Lipoprotein Cholesterol Determines Oxidative Stress and Endothelial Dysfunction in Saphenous Veins From Patients With Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 218 - 223. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kuroda, K. Nakagawa, T. Yamasaki, K.-i. Nakamura, R. Takeya, F. Kuribayashi, S. Imajoh-Ohmi, K. Igarashi, Y. Shibata, K. Sueishi, et al. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells Genes Cells, December 1, 2005; 10(12): 1139 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Meurer, S. Pioch, S. Gross, and W. Muller-Esterl Reactive Oxygen Species Induce Tyrosine Phosphorylation of and Src Kinase Recruitment to NO-sensitive Guanylyl Cyclase J. Biol. Chem., September 30, 2005; 280(39): 33149 - 33156. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Kittleson and J. M. Hare Xanthine oxidase inhibitors: an emerging class of drugs for heart failure Eur. Heart J., August 1, 2005; 26(15): 1458 - 1460. [Full Text] [PDF] |
||||
![]() |
M. S. Wolin, M. Ahmad, and S. A. Gupte Oxidant and redox signaling in vascular oxygen sensing mechanisms: basic concepts, current controversies, and potential importance of cytosolic NADPH Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L159 - L173. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zitouni, J. Nourooz-Zadeh, D. Harry, S. M. Kerry, D. J. Betteridge, F. P. Cappuccio, and K. A. Earle Race-Specific Differences in Antioxidant Enzyme Activity in Patients With Type 2 Diabetes: A potential association with the risk of developing nephropathy Diabetes Care, July 1, 2005; 28(7): 1698 - 1703. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Y. Raju, L. A. Barouch, and J. M. Hare Nitric Oxide and Oxidative Stress in Cardiovascular Aging Sci. Aging Knowl. Environ., May 25, 2005; 2005(21): re4 - re4. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Starling Inducible Nitric Oxide Synthase in Severe Human Heart Failure: Impact of Mechanical Unloading J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1425 - 1427. [Full Text] [PDF] |
||||
![]() |
J. O. Lundberg and E. Weitzberg NO Generation From Nitrite and Its Role in Vascular Control Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 915 - 922. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ohtsubo, I. I. Rovira, M. F. Starost, C. Liu, and T. Finkel Xanthine Oxidoreductase Is an Endogenous Regulator of Cyclooxygenase-2 Circ. Res., November 26, 2004; 95(11): 1118 - 1124. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bonaventura and A. Gow NO and superoxide: Opposite ends of the seesaw in cardiac contractility PNAS, November 23, 2004; 101(47): 16403 - 16404. [Full Text] [PDF] |
||||
![]() |
J. M. Hare Nitroso-Redox Balance in the Cardiovascular System N. Engl. J. Med., November 11, 2004; 351(20): 2112 - 2114. [Full Text] [PDF] |
||||
![]() |
S. A. Khan, K. Lee, K. M. Minhas, D. R. Gonzalez, S. V. Y. Raju, A. D. Tejani, D. Li, D. E. Berkowitz, and J. M. Hare From the Cover: Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling PNAS, November 9, 2004; 101(45): 15944 - 15948. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Eltzschig and C. D. Collard Vascular ischaemia and reperfusion injury Br. Med. Bull., October 19, 2004; 70(1): 71 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Webb, R. Bond, P. McLean, R. Uppal, N. Benjamin, and A. Ahluwalia Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage PNAS, September 14, 2004; 101(37): 13683 - 13688. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Lowenstein Exogenous Thioredoxin Reduces Inflammation in Autoimmune Myocarditis Circulation, September 7, 2004; 110(10): 1178 - 1179. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |